Translation-X, founded in 2022 as a spin-out from the Biozentrum at the University of Basel, is developing brain-penetrant MNK inhibitors aimed at restoring normal mRNA translation and neural function in a genetically defined subgroup of autism spectrum disorder (ASD). The company focuses initially on rare genetic conditions and is building a phenotyping approach to identify a mechanistically defined larger target population. Its lead therapeutic approach targets dysregulated selective mRNA translation, with MNK inhibition positioned to address core ASD pathology. Translation-X believes its candidates could qualify for orphan drug designation, supporting strategic market entry and later expansion. The startup has advanced programs through hit identification and intends to use new funds to propel its drug discovery from the hit to the lead stage. The recent financing improves its investment readiness and access to networks via the Venture Kick program.

Total raised

$0M

Funding rounds

1

Latest round

Seed

Latest activity

Oct 2024